DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Premature
Ejaculation – Pipeline Review, H1 2016” report to their
This report provides comprehensive information on the therapeutic
development for Premature Ejaculation, complete with comparative
analysis at various stages, therapeutics assessment by drug target,
mechanism of action (MoA), route of administration (RoA) and molecule
type, along with latest updates, and featured news and press releases.
It also reviews key players involved in the therapeutic development for
Premature Ejaculation and special features on late-stage and
The report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. It
strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products.
Key Topics Covered:
- Premature Ejaculation Overview
- Therapeutics Development
- Pipeline Products for Premature Ejaculation – Overview
- Pipeline Products for Premature Ejaculation – Comparative Analysis
- Premature Ejaculation – Therapeutics under Development by Companies
Premature Ejaculation – Therapeutics under Investigation by
- Premature Ejaculation Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Premature Ejaculation – Products under Development by Companies
Premature Ejaculation – Products under Investigation by
- Premature Ejaculation – Companies Involved in Therapeutics Development
- Allergan Plc
- Aytu BioScience, Inc.
- Ixchelsis Limited
- NeuroHealing Pharmaceuticals Inc.
- Plethora Solutions Holdings Plc
- SK Chemicals Co., Ltd.
For more information visit http://www.researchandmarkets.com/research/94qbf6/premature
Research and Markets
Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Fax (outside U.S.): +353-1-481-1716
and Reproductive Health Drugs